PURPOSE: To examine the significance of the proposed International Association for the Study of @entity2 , American @entity1514 Society, and European Respiratory Society (IASLC/ATS/ERS) histologic subtypes of @entity2220 for patterns of recurrence and, among @entity1 who recur following resection of @entity2 , for @entity1349 ( @entity1349 ). @entity1 AND METHODS: We reviewed @entity1 with @entity2 who had undergone complete surgical resection from 1999 to 2009 (N = 1,120). @entity5 were subtyped by using the IASLC/ATS/ERS classification. The effects of the dominant subtype on recurrence and, among @entity1 who recurred, on @entity1349 were investigated. RESULTS: Of 1,120 @entity1 identified, 188 had recurrent disease, 103 of whom died as a result of @entity2 . Among @entity1 who recurred, 2-year @entity1349 was 45%, and median @entity1349 was 26.1 months. Compared with @entity1 with @entity5 , @entity1 with solid predominant @entity5 had earlier (P = .007), more extrathoracic (P < .001), and more multisite (P = .011) recurrences. Multivariable analysis of @entity5 factors revealed that, among @entity1 who recurred, solid predominant histologic pattern in the @entity5 (hazard ratio [HR], 1.76; P = .016), age older than 65 years (HR, 1.63; P = .01), and sublobar resection (HR, 1.6; P = .01) were significantly associated with worse @entity1349 . Presence of extrathoracic @entity3 (HR, 1.76; P = .013) and age older than 65 years at the time of recurrence (HR, 1.7; P = .014) were also significantly associated with worse @entity1349 . CONCLUSION: In @entity1 with stage I primary @entity2220 , solid predominant subtype is an independent predictor of early recurrence and, among those @entity1 who recur, of worse @entity1349 . Our findings provide a rationale for investigating adjuvant therapy and identify novel therapeutic targets for @entity1 with solid predominant @entity2220 .

Solid Predominant Histologic Subtype in Resected XXXX Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Tumors', 'tumors', 'nonsolid tumors', 'primary tumor'] @entity2 :: ('MESH:D008175', 'Disease') :: ['stage I lung adenocarcinoma', 'lung cancer', 'Lung Cancer'] @entity1514 :: ('MESH:D013896', 'Disease') :: ['Thoracic'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity2220 :: ('MESH:C538231', 'Disease') :: ['lung adenocarcinoma'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['PRS', 'postrecurrence survival']
@entity2 :: (MESH:D008175,Disease) :: ['Stage I Lung Adenocarcinoma']
